Remimazolam Besylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Remimazolam Besylate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Remimazolam Besylate can convert its Small molecule drug profile and GABAA receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Remimazolam Besylate (query alias: Remimazolam Besylate) |
|---|---|
| Modality / target | Small molecule drug; GABAA receptor; GABAA receptor agonists |
| Highest global status | Approved |
| Originator | PAION AG |
| Active developers | PAION AG, Acacia Pharma Ltd., Paion UK Ltd. |
The MCP disease footprint includes Sedation, Anesthesia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07620782 | Not Applicable | Recruiting | 80 | Interaction coefficient (α) between remimazolam and sevoflurane derived from the Minto response surface model |
| NCT07674719 | Not Applicable | Not yet recruiting | 78 | Acute kidney injury |
| ChiCTR2600126674 | Not Applicable | Not yet recruiting | 72 | Mechanical pain thresholds were assessed via pinprick testing within 1 cm of the surgical incision site and at the nondominant forearm at baseline (preoperatively), during PACU (Post-Anesthesia Care U |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Efficacy and safety of remimazolam besylate in patients receiving mechanical ventilation: A randomized phase Ⅱa trial
Phase 2; n=33; evaluation: Positive. Reported fields: Adverse drug reactions = 4.0 Pts ; Adverse drug reactions = 7.0 Pts ; Adverse drug reactions = 6.0 Pts
Short-term light sedation with remimazolam besylate versus propofol in the ICU (SHOSREB): a multicentre, randomized, single-blind, controlled trial
Phase 3; n=164; evaluation: Non-inferior. Reported fields: Successful sedation = 97.5 % ; Successful sedation = 97.5 %
The 90% Effective Dose (ED90) of Remimazolam Anesthesia Induction in Painless Bidirectional Endoscopy in Children: a Biased Coin up and Down Sequential Trial
Not Applicable; n=165; evaluation: not stated. Reported fields: Modified Observer's Assessment of Alertness/Sedation Scale, MOAA/S(Mean) = 0.674 units on a scale (90% Confidence Interval, 0.66 - 0.76); Modified Observer's Assessment of Alertness/Sedation Scale, MOAA/S(Mean) = 0.937 units on a scale (90% Confidence Interval, 0.65 - 1.264); Modified Observer's Assessment of Alertness/Sedation Scale, MOAA/S(Mean) = 0.449 units on a scale (90% Confidence Interval, 0.423 - 0.59)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Remimazolam Besylate addresses Sedation, Anesthesia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 9 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-01-19 | PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE CRISTÁLIA IN BRASIL | Approved | Financial terms not disclosed |
| 2022-11-16 | PAION AG enters partnership with Viatris and expands sales activities in Europe | Approved | Financial terms not disclosed |
| 2022-03-28 | Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc | Not disclosed | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Method for preparing remimazolam besylate with high efficiency”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 24 July 2026. Counts and status fields may change as source records update.
